SCHEMBL14745369

SCHEMBL14745369

CCc1cc(C(=O)OC)c(=O)n(Cc2ccc(OC)cc2OC)c1-c1ccc2c(c1)cc(C=O)n2C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.39
GABRG2 P18507 5/20 0.38
GABRB3 P28472 5/20 0.38
GABRA3 P34903 5/20 0.38
GABRA2 P47869 4/20 0.38
GABRA1 P14867 3/20 0.38
GABRA5 P31644 2/20 0.38
MAPT P10636 3/20 0.36
RAB9A P51151 2/20 0.36
ALDH1A1 P00352 2/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
MAPK1 P28482 1/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TP53 P04637 2/20 0.36
NPC1 O15118 1/20 0.36
PKM P14618 1/20 0.36
MAOA P21397 1/20 0.36
EDNRB P24530 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14745624 0.88 GABRG2 (0.40) L3MBTL1GABRG2GABRB3GABRA3GABRA2
SCHEMBL14745593 0.86 GABRG2 (0.39) L3MBTL1GABRG2GABRB3GABRA3GABRA2
SCHEMBL14745444 0.83 LMNA (0.40) L3MBTL1MAPTALDH1A1MEN1POLB
SCHEMBL14745163 0.82 EDNRB (0.40) MAPTRAB9AALDH1A1MEN1POLB
SCHEMBL14744995 0.82 L3MBTL1 (0.36) L3MBTL1GABRG2GABRB3GABRA3GABRA2
SCHEMBL14745231 0.82 L3MBTL1 (0.36) L3MBTL1GABRG2GABRB3GABRA3GABRA2
SCHEMBL14745992 0.82 L3MBTL1 (0.35) L3MBTL1GABRG2GABRB3GABRA3GABRA2
SCHEMBL14744608 0.82 EDNRB (0.42) MAPTRAB9AALDH1A1MEN1POLB
SCHEMBL14745536 0.81 MAOA (0.40) MAPTALDH1A1MEN1POLBMAPK1
SCHEMBL14744696 0.81 L3MBTL1 (0.34) L3MBTL1GABRG2GABRB3GABRA3GABRA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP L3MBTL1 321/4885GABRG2 3111/4885GABRB3 2579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.